Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells

Immunopharmacology

Volumn 42, Issue 1-3, 1999, Pages 175-185

  Paas, Yoav ^a   Bohana Kashtan, Osnat ^b   Fishelson, Zvi ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

C9; CK2; Complement; Ecto PK; Phosphorylation

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; CASEIN KINASE II; COMPLEMENT COMPONENT C9; HEPARIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SERINE; THROMBIN; ZINC CHLORIDE;

ALKYLATION; AMINO TERMINAL SEQUENCE; CELL STRAIN K 562; CONFERENCE PAPER; CONTROLLED STUDY; HEMOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REDUCTION; STOICHIOMETRY;

EID: 0032992085     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00027-2     Document Type: Conference Paper

References (51)

1. Allende J.E., Allende C.C. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 9:1995;313-323.
2. Behrens M.M., Mazon M.J. Yeast cAMP-dependent protein kinase can be associated to plasma membrane. Biochem. Biophys. Res. Commun. 151:1988;561-567.
3. Biesecker G., Müller-Eberhard H.J. The ninth component of human complement: purification and physicochemical characterization. J. Immunol. 124:1980;1291-1296.
4. Biesecker G., Gerard C., Hugli T.E. An amphiphilic structure of the ninth component of human complement. J. Biol. Chem. 257:1982;2584-2590.
5. Boyle M.D., Ohanian S.H., Borsos T. Studies on the terminal stages of antibody-complement-mediated lysis of a tumor cell: II. Inhibition of transformation of T* to dead cells by 3′5′ cAMP. J. Immunol. 116:1976;1276-1279.
6. Carney D.F., Koski C.L., Shin M.L. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 134:1985;1804-1809.
7. Chijiwa T., Hagiwara M., Hidaka H. A newly synthesized selective casein kinase I inhibitor N-(-2-aminoethyl)-5-chloro isoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J. Biol. Chem. 264:1989;4924-4927.
8. Cooper J.A., Sefton B.M., Hunter T. Detection and quantification of phosphotyrosine in proteins. Meth. Enzymol. 99:1983;387-402.
9. De Pierre J.W., Karnovsky M.L. Plasma membranes of mammalian cells. J. Cell Biol. 56:1973;275-303.
10. DiScipio R.G., Gehring M.R., Podack E.R., Kan C.C., Hugli T.E., Fey G.H. Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc. Natl. Acad. Sci. USA. 81:1984;7298-7302.
11. Fishelson Z., Kraus S. Cell desensitization to lysis by treatment with sublytic complement doses depends upon a protein kinase cascade. Mol. Immunol. 35:1998;346.
12. Fishelson Z., Kopf E., Reiter Y. Phosphorylation, phosphatidylinositol turnover and resistance to complement damage. FASEB J. 2:1988;A872.
13. Fishelson Z., Kopf E., Paas Y., Ross L., Reiter Y. Protein phosphorylation as a mechanism of resistance against complement damage. Prog. Immunol. 7:1989;205-208.
14. Gordon J.L. Extracellular ATP: effects, sources and fate. Biochem. J. 233:1986;309-319.
15. Hathaway G.M., Traugh J.A. Casein kinase II. Meth. Enzymol. 99:1983;317-331.
16. Hathaway G.M., Lubben T.H., Traugh J.A. Inhibition of casein kinase 2 by heparin. J. Biol. Chem. 255:1980;8038-8041.
17. Hermoso T., Fishelson Z., Becker S.I., Hirschberg K., Jaffe C.L. Leishmanial protein kinases phosphorylate components of the complement system. EMBO J. 10:1991;4061-4067.
18. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinoline sulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 23:1984;5036-5041.
19. Jean D., Bar-Eli M., Huang S., Xie K., Rodrigues-Lima F., Hermann J., Frade R. A cystein proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56:1996;254-258.
20. Juhl H., Helmig F., Baltzer K., Kalthoff H., Henne-Bruns D., Kremer B. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol. 64:1997;222-230.
21. Jurianz, K., Maslak, S., Fishelson, Z., Kirschfink, M., 1998. Neutralization of complement regulatory proteins augments lysis of mammary carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology (in press).
22. Koski C.L., Ramm L.E., Hammer C.H., Mayer M.M., Shin M.L. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc. Natl. Acad. Sci. USA. 80:1983;3816-3820.
23. Kubler D., Pyerin W., Burow E., Kinzel V. Substrate-effected release of surface-located protein kinase from intact cells. Proc. Natl. Acad. Sci. USA. 80:1983;4021-4025.
24. Kubler D., Pyerin W., Bill O., Hotz A., Sonka J., Kinzel V. Evidence for ecto-protein kinase activity that phosphorylates Kemptide in a cyclic AMP-dependent mode. J. Biol. Chem. 264:1989;14549-14555.
25. Kuenzel E.A., Mulligan J.A., Sommercorn J., Krebs E.G. Substrate specificity determinants for casein kinase II as deduced from studies with synthetic peptides. J. Biol. Chem. 262:1987;9136-9140.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. Lo T.N., Boyle M.D.P. Relationship between the intracellular cyclic adenosine 3′: 5′-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement. Cancer Res. 39:1979;3156-3162.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Maenpaa A., Junnikkala S., Hakulinen J., Timonen T., Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148:1996;1139-1152.
30. Maison C.M., Villiers C.L., Colomb M.G. Proteolysis of C3 on U937 cell plasma membranes. J. Immunol. 147:1991;921-926.
31. Martin S.C. Phosphorylation of complement factor C3 in vivo. Biochem. J. 261:1989;1051-1054.
32. Morgan B.P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264:1989;1-14.
33. Morgan B.P., Campbell A.K. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem. J. 231:1985;205-208.
34. Morgan B.P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:1994;369-396.
35. Morgan B.P., Dankert J.R., Esser A.F. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J. Immunol. 138:1987;246-253.
36. Müller-Eberhard H.J. The membrane attack complex of complement. Annu. Rev. Immunol. 4:1986;503-528.
37. Nilsson Ekdahl K., Nilsson B. Phosphorylation of complement C3 and C3 fragments by a human platelet protein kinase. J. Immunol. 154:1995;6502-6510.
38. Nilsson Ekdahl K., Nilsson B. Phosphorylation of complement component C3 after synthesis in U937 cells by a putative protein kinase, casein kinase 2, which is regulated by CD11b: evidence that membrane-bound proteases preferentially cleave phosphorylated C3. Biochem. J. 328:1997;625-633.
39. Ohanian S.H., Schlager S.I. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. CRC Crit. Rev. Immunol. 1:1981;165-209.
40. Paas Y., Fishelson Z. Shedding of tyrosine and serine/threonine ecto-protein kinases from human leukemic cells. Arch. Biochem. Biophys. 316:1995;780-788.
41. Pinna L.A. Casein kinase II: an 'eminence grise' in cellular regulation? Biochem. Biophys. Acta. 1054:1990;267-284.
42. Pinna L.A. A historical view of protein kinase CKII. Cell. Mol. Biol. Res. 40:1994;383-390.
43. Reiter Y., Fishelson Z. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP). Mol. Immunol. 29:1992;771-781.
44. Schlager S.I., Ohanian S.H. Tumor cell lipid composition and sensitivity to humoral immune killing: II. Influence of plasma membrane and intracellular lipid and fatty acid content. J. Immunol. 125:1980;508-517.
45. Skubitz K.M., Ehresmann D.D., Ducker T.P. Characterization of human neutrophil ecto-protein kinase activity released by kinase substrates. J. Immunol. 147:1991;638-650.
46. Stanley K.K., Newby A.C., Luzio J.P. What do ectoenzymes do? TIBS. 7:1982;145-147.
47. Stanley K.K., Kocher H.P., Luzio J.P., Jackson P., Tschopp J. The sequence and topology of human complement component C9. EMBO J. 4:1985;375-382.
48. Stanley K.K., Page M., Campbell A.K., Luzio J.P. A mechanism for the insertion of complement component C9 into target membranes. Mol. Immunol. 23:1986;451-458.
49. Tschopp J. Circular polymerization of the membranolytic ninth component of complement: dependence on metal ions. J. Biol. Chem. 259:1984;10569-10573.
50. Tschopp J., Podack E.R., Muller-Eberhard H.J. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization. J. Immunol. 134:1985;495-499.
51. Walter J., Schnolzer M., Pyerin W., Kinzel V., Kubler D. Induced release of cell surface protein kinase yields CK1 and CK2 like enzymes in tandem. J. Biol. Chem. 271:1996;111-119.